157 related articles for article (PubMed ID: 25934889)
1. IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
Carson CC; Moschos SJ; Edmiston SN; Darr DB; Nikolaishvili-Feinberg N; Groben PA; Zhou X; Kuan PF; Pandey S; Chan KT; Jordan JL; Hao H; Frank JS; Hopkinson DA; Gibbs DC; Alldredge VD; Parrish E; Hanna SC; Berkowitz P; Rubenstein DS; Miller CR; Bear JE; Ollila DW; Sharpless NE; Conway K; Thomas NE
Clin Cancer Res; 2015 May; 21(9):2167-76. PubMed ID: 25934889
[TBL] [Abstract][Full Text] [Related]
2. Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.
Schönherr M; Bhattacharya A; Kottek T; Szymczak S; Köberle M; Wickenhauser C; Siebolts U; Saalbach A; Koczan D; Magin TM; Simon JC; Kunz M
Pigment Cell Melanoma Res; 2014 May; 27(3):418-30. PubMed ID: 24406113
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.
Merzoug-Larabi M; Spasojevic C; Eymard M; Hugonin C; Auclair C; Karam M
BMC Cancer; 2017 Jan; 17(1):12. PubMed ID: 28056869
[TBL] [Abstract][Full Text] [Related]
6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
10. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
12. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
[TBL] [Abstract][Full Text] [Related]
13. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
14. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
15. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
[TBL] [Abstract][Full Text] [Related]
16. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
Scortegagna M; Lau E; Zhang T; Feng Y; Sereduk C; Yin H; De SK; Meeth K; Platt JT; Langdon CG; Halaban R; Pellecchia M; Davies MA; Brown K; Stern DF; Bosenberg M; Ronai ZA
Cancer Res; 2015 Apr; 75(7):1399-412. PubMed ID: 25712345
[TBL] [Abstract][Full Text] [Related]
17. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
18. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
19. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
[TBL] [Abstract][Full Text] [Related]
20. Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells.
Hartmann RR; Rimoldi D; Lejeune FJ; Carrel S
Melanoma Res; 1997 Aug; 7 Suppl 2():S27-33. PubMed ID: 9578414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
